

## Innovations in Bioassays for Drug Discovery & Development

Recent advances in discovery sciences and technologies are enabling R&D professionals to embrace new challenges in drug discovery. New opportunities are open to face the decrease of attrition in translation while optimising operational efficiency. Furthermore, the COVID-19 pandemic has questioned the way we are working in the lab; we are living transformational times. We will share a personal view on trends, disruptions, challenges, and opportunities in screen design and relevant bioassay technology. We will raise issues such as assay reproducibility with personalised samples, evolution from life sciences to information sciences, transformation of classical discovery labs into smart and cloud labs, assay design for precious native samples, while maximising the information we can extract from live cells and in vivo models. We hope to bring up reflection points which may ignite present and future discussions.

### Moderator:

- **Gijs J. Jochems**, CEO, Promega Biotech Ibérica

### Speakers:

- **Maria Jurado**, Application Support Scientist, Promega Biotech Ibérica, (Spain) – *Bioluminescence for drug discovery*
- **Elena Rivas**, CEO, A4Cell, (Spain) – *Nanoparticles to measure physiological parameters in living cells*
- **Susana Pascoal**, CSO, IKAN BIOTECH (Spain) – *The value of the zebrafish model for drug development*
- **José Julio Martín**, SLAS – The Society for Laboratory Automation and Screening (Spain representative) – *The transformation in bioassays for drug discovery.*